The latter findings point towards a key role of SCD1 in controlling TG accumulation and SVZ NSC dysfunction in AD, and argues for SCD1 inhibitors being a promising therapeutic tool to attenuate early pathological hallmarks in AD. This evidence concerns the gene SCD and Alzheimer disease.